相关实验视频

Updated: May 29, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.6K

CD4+ T-细胞淋巴瘤在TP53中携带化学抗原受体集成

Karlo Perica1,2, Nayan Jain2, Michael Scordo1,3,4

  • 1Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.

The New England journal of medicine
|February 5, 2025
PubMed
概括

汽车T细胞治疗可以导致T细胞淋巴瘤. 在BCMA CAR T细胞疗法后患有T细胞淋巴瘤的患者中发现了瘤抑制剂TP53中的lentiviral集成.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.1K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

988

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464